This Article Full Text Full Text (PDF) Other Versions of this Article: JCM.00491-07v1 45/9/2793    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Munson, E. Articles by Hryciuk, J. E. Search for Related Content PubMed PubMed Citation Articles by Munson, E. Articles by Hryciuk, J. E.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2007, p. 2793-2797, Vol. 45, No. 9
0095-1137/07/$08.00+0     doi:10.1128/JCM.00491-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Evaluation of Gen-Probe APTIMA-Based Neisseria gonorrhoeae and Chlamydia trachomatis Confirmatory Testing in a Metropolitan Setting of High Disease Prevalence

Wheaton Franciscan and Midwest Clinical Laboratories, Wauwatosa, Wisconsin 53226,¹ College of Health Sciences, University of Wisconsin—Milwaukee, Milwaukee, Wisconsin 53201²

Received 5 March 2007/ Returned for modification 17 May 2007/ Accepted 11 June 2007

Prompted by reports challenging the validity of the low-positive Neisseria gonorrhoeae and Chlamydia trachomatis results generated by the APTIMA Combo 2 assay (Gen-Probe, Incorporated) and by a Centers for Disease Control and Prevention recommendation to confirm N. gonorrhoeae- or C. trachomatis-positive screens by using an alternative amplification target, we report on a comparison of this means of confirmation with an in-house algorithm of repeat testing. Primary clinical specimens yielding N. gonorrhoeae- or C. trachomatis-specific luminescent values between 100,000 and 1,000,000 were repeat tested in duplicate. A subset of specimens was forwarded for confirmatory assays (Gen-Probe) individualized for alternative N. gonorrhoeae or C. trachomatis targets. An 18-month audit revealed that 230 of 29,977 C. trachomatis screens (0.8%) and 41 of 29,064 N. gonorrhoeae assays (0.1%) yielded low-positive data. When a subset of 40 low-positive N. gonorrhoeae screens was repeat tested, 20 (50.0%) remained positive; 22 (55.0%) of the screens remained positive following performance of the confirmatory assay. In contrast, repeat testing of 153 low-positive C. trachomatis screens yielded a positive result for fewer specimens (n = 97; 63.4%) than when commercial confirmatory testing was used (n = 124; 81.0%). However, confirmation of the results for additional C. trachomatis screens by use of an alternative target did not translate into significant differences in the calculated overall C. trachomatis-positive screen rates (7.39% by repeat testing versus 7.52% by the confirmatory assay; P = 0.53). Furthermore, use of the confirmatory assay raised the positive predictive value only 1.8% over that of repeat testing. Molecular confirmatory testing did not significantly enhance the reliability of C. trachomatis- or N. gonorrhoeae-specific nucleic acid amplification testing in this metropolitan setting compared to the reliability of repeat testing.

Published ahead of print on 20 June 2007.